Table of Contents
- Product Overview
- Technical Specifications & Comparison
- Key Applications
- Usage Case Studies
- Client Success Stories
- Request Quotation
Triclabendazole CAS 68786-66-3 Overview
Basic Chemical Properties
| Parameter | Specification |
|---|---|
| CAS Number | 68786-66-3 |
| Chemical Name | 5-Chloro-6-(2,3-dichlorophenoxy)-2-methylsulfanyl-1H-benzimidazole |
| Molecular Formula | C14H9Cl3N2OS |
| Appearance | White to off-white crystalline powder |
| Purity | ≥99% (HPLC) |
Comparative Analysis
| Feature | Triclabendazole | Alternative Anthelmintics |
|---|---|---|
| Spectrum | Broad-spectrum (adult & larval stages) | Stage-specific efficacy |
| Bioavailability | 95% oral absorption | 60-80% absorption rate |
Technical Specifications
Pharmaceutical Grade Parameters
| Test Item | Specification Limit |
|---|---|
| Heavy Metals | ≤10 ppm |
| Residual Solvents | Complies with ICH Q3C |
Therapeutic Applications
Human Medicine
First-line treatment for fascioliasis (liver fluke infection) with 97-100% efficacy in single-dose regimens (10mg/kg).
Veterinary Use
Effective against Fasciola hepatica in cattle with 99% reduction in egg output post-treatment.
Clinical Implementation Cases
Case Study 1: Endemic Area Eradication
Bolivian public health program (2022) achieved 89% reduction in fascioliasis prevalence through mass drug administration.
Case Study 2: Veterinary Application
Australian cattle farm reduced liver condemnation rates from 35% to 2% with strategic dosing protocols.
Client Implementations
Pharmaceutical Manufacturer – Germany
“Consistent 99.8% purity batches enabled seamless EU GMP certification for our anthelmintic formulations.”
Research Institute – USA
“Supplied analytical-grade material that met USP testing standards for our novel drug delivery system development.”
Contact for Technical Documentation
Request Product Dossier
Email: info@vivalr.com
Tel: (86) 15866781826
Quality Assurance Documentation
- Certificate of Analysis (CoA)
- Stability Data Packages
- GMP Compliance Statements



评论
目前还没有评论。